(Changes to Disclosed Information) Notice Regarding the Discontinuation of In-House Development in Japan of a Regenerative Medicine Product Approved for Manufacture and Marketing in India | MEDINET Co.,Ltd. (2370) timely disclosure

Worth reading

20Immaterial

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Conditional

How definitive the wording is.

Items stated in the management plan

Publication date30 October 2026

This document does not state the plan name, plan period, or numerical targets.

Key initiatives

01Focus management resources on the Company’s core cell processing business

02Consolidate R&D projects with a focus on their potential application to the cell processing business

03Consider the possibility of continued development in Japan by a third party through partnerships with external companies, sublicensing or business transfers

Reason for revision or withdrawal

This decision was made after comprehensively considering the progress of R&D, the future investment burden and the outlook for commercialization, with the aim of improving profitability and strengthening the financial base, and therefore reviewing the allocation of investment and personnel related to R&D for regenerative medicine products and focusing management resources on the Company’s core cell processing business.

Items stated in the management plan
Item	Details
Key initiatives	Focus management resources on the Company’s core cell processing business, Consolidate R&D projects with a focus on their potential application to the cell processing business, Consider the possibility of continued development in Japan by a third party through partnerships with external companies, sublicensing or business transfers
Reason for revision or withdrawal	This decision was made after comprehensively considering the progress of R&D, the future investment burden and the outlook for commercialization, with the aim of improving profitability and strengthening the financial base, and therefore reviewing the allocation of investment and personnel related to R&D for regenerative medicine products and focusing management resources on the Company’s core cell processing business.
Publication date	30 October 2026

Items this document does not state (22)

Plan namePlan periodProgress against the planSales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorSegment targetNon-financial targetsPlan assumptionsResults under the previous planSize of the Target MarketRisks identifiedDate of board resolution

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.